Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ITCI Intra-Cellular Therapies	$131.87	$130.48	$64.09 ▼ $131.98	$14.05B	0.69	1.50 million shs	N/A
SMMT Summit Therapeutics	$23.34 -5.2%	$19.88	$2.10 ▼ $33.89	$17.23B	-0.46	2.81 million shs	544,559 shs
SRPT Sarepta Therapeutics	$53.90 -1.0%	$85.66	$48.01 ▼ $173.25	$5.23B	0.93	1.39 million shs	93,957 shs
TEVA Teva Pharmaceutical Industries	$13.38 -1.7%	$15.64	$12.47 ▼ $22.80	$15.17B	0.72	12.45 million shs	920,763 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ITCI Intra-Cellular Therapies	0.00%	0.00%	+0.46%	+4.07%	+103.63%
SMMT Summit Therapeutics	-5.78%	+47.96%	+18.42%	+35.27%	+573.60%
SRPT Sarepta Therapeutics	-0.38%	+10.39%	-44.01%	-54.40%	-54.00%
TEVA Teva Pharmaceutical Industries	+0.04%	+0.37%	-17.04%	-37.97%	+2.68%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ITCI Intra-Cellular Therapies	3.491 of 5 stars	2.2	3.0	0.0	4.5	3.5	1.7	0.6
SMMT Summit Therapeutics	2.4651 of 5 stars	4.5	1.0	0.0	0.0	2.7	1.7	0.0
SRPT Sarepta Therapeutics	4.6807 of 5 stars	4.4	2.0	0.0	4.2	2.9	2.5	1.9
TEVA Teva Pharmaceutical Industries	3.0338 of 5 stars	3.4	5.0	0.8	0.0	2.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ITCI Intra-Cellular Therapies	2.33	Hold	$106.23	-19.44% Downside
SMMT Summit Therapeutics	3.00	Buy	$35.40	51.67% Upside
SRPT Sarepta Therapeutics	2.83	Moderate Buy	$161.83	200.22% Upside
TEVA Teva Pharmaceutical Industries	2.86	Moderate Buy	$23.43	75.17% Upside

Current Analyst Ratings Breakdown

Latest SRPT, SMMT, TEVA, and ITCI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$75.00 ➝ $75.00
4/11/2025	SRPT Sarepta Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$196.00 ➝ $182.00
4/11/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$115.00
4/3/2025	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$202.00 ➝ $183.00
4/2/2025	ITCI Intra-Cellular Therapies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$132.00 ➝ $132.00
4/2/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$75.00 ➝ $75.00
3/31/2025	SRPT Sarepta Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$161.00 ➝ $87.00
3/26/2025	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$35.00
3/26/2025	SMMT Summit Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$23.00 ➝ $35.00
3/21/2025	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
3/20/2025	SRPT Sarepta Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$105.00 ➝ $80.00

(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ITCI Intra-Cellular Therapies	$680.50M	20.64	N/A	N/A	$6.15 per share	21.44
SMMT Summit Therapeutics	$700K	24,596.36	N/A	N/A	$0.11 per share	212.18
SRPT Sarepta Therapeutics	$1.90B	2.75	N/A	N/A	$9.19 per share	5.87
TEVA Teva Pharmaceutical Industries	$16.54B	0.92	$2.65 per share	5.05	$4.75 per share	2.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ITCI Intra-Cellular Therapies	-$139.67M	-$0.73	N/A	694.05	N/A	-14.07%	-9.93%	-8.38%	5/6/2025 (Estimated)
SMMT Summit Therapeutics	-$614.93M	-$0.31	N/A	N/A	N/A	N/A	-85.42%	-52.66%	4/29/2025 (Estimated)
SRPT Sarepta Therapeutics	-$535.98M	$2.28	43.11	4.93	N/A	7.43%	11.00%	3.35%	4/29/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.45	N/A	5.09	1.44	-9.91%	42.46%	6.65%	5/7/2025 (Estimated)

Latest SRPT, SMMT, TEVA, and ITCI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	N/A	N/A	N/A	$685.75 million	N/A
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	N/A	N/A	N/A	$3.99 billion	N/A
4/29/2025	Q1 2025	SMMT Summit Therapeutics	-$0.0715	N/A	N/A	N/A	N/A	N/A
2/24/2025	Q4 2024	SMMT Summit Therapeutics	-$0.08	-$0.08	N/A	-$0.08	N/A	$0.20 million
2/21/2025	Q4 2024	ITCI Intra-Cellular Therapies	-$0.08	-$0.16	-$0.08	-$0.16	$205.08 million	$199.22 million
1/29/2025	Q4 2024	TEVA Teva Pharmaceutical Industries	$0.69	$0.70	+$0.01	-$0.19	$4.10 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ITCI Intra-Cellular Therapies	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	7.56%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ITCI Intra-Cellular Therapies	N/A	7.66	7.51
SMMT Summit Therapeutics	N/A	8.31	8.31
SRPT Sarepta Therapeutics	0.93	3.84	3.03
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ITCI Intra-Cellular Therapies	92.33%
SMMT Summit Therapeutics	4.61%
SRPT Sarepta Therapeutics	86.68%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
ITCI Intra-Cellular Therapies	2.60%
SMMT Summit Therapeutics	88.30%
SRPT Sarepta Therapeutics	7.70%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ITCI Intra-Cellular Therapies	560	106.52 million	103.56 million	Optionable
SMMT Summit Therapeutics	110	737.68 million	86.28 million	Optionable
SRPT Sarepta Therapeutics	840	97.03 million	88.17 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.13 billion	1.13 billion	Optionable

SRPT, SMMT, TEVA, and ITCI Headlines

Recent News About These Companies

Stock Traders Buy High Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

April 16 at 3:02 AM | americanbankingnews.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is Menora Mivtachim Holdings LTD.'s 6th Largest Position

April 15 at 8:57 AM | marketbeat.com

Invesco Ltd. Increases Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 15 at 4:58 AM | marketbeat.com

APG Asset Management N.V. Has $1.47 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 14 at 5:23 AM | marketbeat.com

Legal & General Group Plc Sells 1,740,342 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 14 at 4:57 AM | marketbeat.com

Sterling Capital Management LLC Sells 237,189 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 13 at 8:11 AM | marketbeat.com

FIL Ltd Sells 79,243 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 13 at 5:35 AM | marketbeat.com

Envestnet Asset Management Inc. Sells 68,650 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 13 at 5:08 AM | marketbeat.com

5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility

April 13 at 3:06 AM | fool.com

Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn

April 11, 2025 | insidermonkey.com

Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn

April 11, 2025 | msn.com

Trexquant Investment LP Takes $2.09 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 11, 2025 | marketbeat.com

Why Teva Pharmaceutical Industries Limited’s (TEVA) Stock Is Down 10.66%

April 10, 2025 | aaii.com

Renaissance Group LLC Sells 20,167 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 10, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Renaissance Technologies LLC

April 10, 2025 | marketbeat.com

325,921 Shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Purchased by Resona Asset Management Co. Ltd.

April 10, 2025 | marketbeat.com

Teva Pharmaceutical Industries (NYSE:TEVA) Pops As FDA Expands AJOVY'S Use For Pediatric Migraine Prevention

April 9, 2025 | finance.yahoo.com

Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Up - Here's Why

April 9, 2025 | marketbeat.com

ADAR1 Capital Management LLC Has $3.23 Million Stock Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

April 9, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Fmr LLC

April 9, 2025 | marketbeat.com

Teva announces FDA acceptance of sBLA for AJOVY

April 8, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRPT, SMMT, TEVA, and ITCI Company Descriptions

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)

As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Summit Therapeutics NASDAQ:SMMT

$23.34 -1.28 (-5.20%)

As of 10:24 AM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Sarepta Therapeutics NASDAQ:SRPT

$53.90 -0.52 (-0.95%)

As of 10:25 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Teva Pharmaceutical Industries NYSE:TEVA

$13.38 -0.23 (-1.65%)

As of 10:25 AM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time